目的:探究阿昔洛韦对小儿传染性单核细胞增多症CD4+、CD8+的影响。方法:选取我院收治的小儿传染性单核细胞增多症的怠者64例。随机分为两组。实验组予阿昔洛韦静脉滴注,对照组予利巴韦林静脉滴注。对比两组的临床疗效及CD4+、CD8+和CD4+/CD8+比值的变化情况。结果:①治疗后两组患儿临床疗效,实验组较对照组显著改善,差异有统计学意5L(P〈0.05)。②治疗后两组患儿退热时间、淋巴结消退时间、异型淋巴细胞消失时间以及住院时间等比较,实验组明显较对照组短,差异有统计学意义(P〈0.05)。③治疗前,两组患者CD4+、CD8+以及CD4+/CD8+比值无统计学差异(P〉0.05);治疗后,患者CD4+及CD4+/CD”比值呈现先升高再降低的趋势,CD8+则呈现下降趋势,与对照组比较,实验组治疗3天,10天及1个月CD4+以及CD8+下降明显,差异具有统计学意义(P〈0.05);CD4+/CD8+比值则较对照组升高(P〈0.05)。结论:采用阿昔洛韦能够更好的改善患者临床症状,影响CD4+、CD8+的变化,使紊乱的免疫系统较快的恢复。
Objective: To explore the influence of acyclovir on the level of CD4+ and CD8+ in infectious mononucleosis in children. Methods: 64 cases from our hospital diagnosed of infectious mononucleosis were selected and randomly divided into two groups, 32 cases in each group. The children in experimental group were administered acyclovir, daily 10 mg/kg, adding to 10% Glucose injection 100 mL, for twice intravenous infusion, 12 days as a treatment course. The control group was treated with ribavirin, daily 10 mg/kg, adding to 0.9% sodium chloride injection (100 mL), for twice intravenous infusion, and 12 days as a treatment course. The clinical curative effect before and aRer treatment, the index of curative effect, the level of CD4+, CD8+ and CD4+/CD8+ ratio on 1st day, 3rd day, 10th day, and 1 month after treatment was compared between two groups. Results: The clinical curative effect of the experimental group was improved significantly compared with that of the control group after the treatment, and the difference was statistically significant (P〈0.05); Comparing the therapeutic index after treatment between the two groups, it was significantly shorter in the experimental group than that of the control group, and the difference was statistically significant (P 〈0.05); Before treatment, no significant difference between the two groups of patients with CD4+, CD4+ and CD4+/CD8+ ratio(P〉0.05); after treatment, for the experimental group, CD4+and the ratio of CD4+/CD8+ was increased firstly and then decreased, while CDs+ was decreased; compared to the control group, CD4+ and CD8+ was decreased significantly in the experimental group in 3rd day, 10th day and 1 month with statistical significance differences (P〈0.05); the ratio of CD4+/CD8+ was higher than that of control group with statistically significant difference (P〈0.05). Conclusions: Acyclovir can significantly improve the clinical symptoms in children with infectious mononucleosis with be